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ABSTRACT
Introduction: Despite opioids’ recognized role
in the treatment of moderate/severe
musculoskeletal chronic pain, their long-term
benefits need investigation. We explored the
lasting analgesic efficacy, tolerability, influence
on life quality, and chronicity stage of the novel
prolonged release (PR) opioid, tapentadol, in 30
outpatients.
Methods: We evaluated patients’ pain intensity
and relief (Numerical Rating Scale; NRS),
adverse effects, sleep quality, treatment
satisfaction, health status (12-questions
Health-Survey; SF-12), chronicity stage (Italian
Mainz Pain-Staging System; I-MPSS) at 10, 30,
60, and 90 days after tapentadol prescription.
Results: At follow-ups, the investigated
outcomes showed an overall statistically
significant (Wilcoxon signed-rank test)
improvement and remained stable over time,
as did the health status and chronicity stage.
Adverse effects were limited, transitory, and
tolerable.
Conclusions: Twelve weeks of PR tapentadol in
outpatients with moderate/severe chronic
musculoskeletal pain showed satisfactory
analgesic efficacy and tolerability, and had a
positive influence on life quality and chronicity
stage. The results are robust enough to warrant a
subsequent study with a larger sample and a
longer observation period.
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INTRODUCTION
Moderate/severe non-cancer chronic pain (CP)
occurs in 19 % of European adults, affecting
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their daily, social, and working lives; most
patients do not receive pain treatment, and 40
% receive inadequate pain treatment [1].
Chronic pain represents a challenge for
orthopedists and pain specialists given its
multiple nature which produces both physical
and psychological suffering, and because
the underlying complex pathophysiological
mechanisms require individualized
management and a pharmacological approach
[2, 3]. The lack of individually tailored
management may lead to inappropriate
treatments, useless analgesic dose escalations,
and the failure of multiple therapies; these may
result in ineffective pain control, harmful
adverse effects, low patient compliance,
therapy discontinuation, and increased
healthcare costs, patient frustration, and
suffering [2–4]. The main goals of CP
pharmacological management are pain control
with a satisfactory quality of life (QoL) and
functional and social recovery [4, 5] both in the
short and long term.
Opioids have a recognized role in the
treatment of moderate/severe non-cancer CP;
however, their lasting benefits in various CP
conditions and in terms of tolerability and QoL
still need further clinical investigation [6, 7].
Many of these issues directly depend upon the
l-receptor agonist activity of opioids. Indeed,
the endogenous opioid system is physiologically
implicated in several vital functions and
homeostatic systems (e.g., respiratory,
gastrointestinal, hormonal, and immune
milieus). Thus, along with analgesia, opioids
may hamper these systems and thereby induce
adverse side effects (e.g., nausea, constipation,
immunodepression, and opioid-induced
androgen-deficiency) that in the long term may
compromise patients’ health conditions and QoL.
To address the need for efficacious, safe, and
well-tolerated analgesics, a new drug, namely
prolonged release (PR) tapentadol, with a dual
mode of action (l-opioid-receptor agonist and
norepinephrine reuptake inhibitor) has been
developed; it is reported to produce both
satisfactory analgesia and a better tolerability
profile due to its limited opioid component
[8–12]. Evidence shows that it is efficacious
and tolerated in patients with cancer and
non-cancer CP [6, 13–22].
We sought to explore, in non-cancer
outpatients with musculoskeletal CP and over
a period of 12 weeks, the lasting PR tapentadol
analgesic efficacy, tolerability profile, and
influence on QoL and chronicity stage as a
first step towards a future trial in which the
long-term efficacy and tolerability profile of PR




This observational study was held at the Acute
and CP center of Bologna’s Teaching Hospital,
Italy. The center is an anesthesiology-based
pain program that provides outpatient
consultation for primary care physicians and
specialty services for inpatients. The sample
included 30 consecutive mixed non-cancer CP
outpatients who were treated with tapentadol
for at least 90 days.
Proceedings, Instruments, and Rationale
The aims of the study were to explore the
lasting analgesic efficacy, tolerability profile,
and influence on patients’ QoL and chronicity
stage of PR tapentadol. Upon recruitment (V0)
and after signed informed consent, patients
went through a thorough physical
examination and history taking for CP
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diagnosis; information on current pain
intensity, medications, and their doses was
also obtained. Other investigated variables
were: primary pathology, gender (male/
female), and age groups (patients were divided
into 20-year interval groups: 30–50,
51–70,[70 years). At the follow-ups (10, 30,
60, and 90 days after V0, respectively) we
collected information on the ongoing pain
therapy, tapentadol dose variations, analgesic
efficacy, tolerability, and patient satisfaction;
the General Health Status and chronicity stage,
by means of the 12-questions Health-Survey (SF-
12) and the Italian Mainz Pain-Staging System
(I-MPSS) questionnaires, were evaluated at V0
and V90, respectively. The SF-12 provides a
multi-dimensional profile of health status and
two summary scores assessing physical function
and mental well-being; the I-MPSS, recently
validated [23], is a measure of pain chronicity
and classifies patients at three chronicity stages
(I mild; II moderate; and III severe). The
rationale for exploring the variables used in
this study was that they all have strong
relevance to the issue of long-term benefits of
opioids in CP conditions both in terms of
efficacy, tolerability, health status, and QoL.
If patients were not available for an office
visit, follow-ups were made by phone. Table 1
reports the investigated variables and tools used
for data collection.
Prolonged release tapentadol was
administered and titrated according to the
therapeutic indications, the dosages and the
instructions given in the summary of the
product characteristics and evidence reported
in the literature [19, 24–27]. In opioid-naı¨ve
patients, PR tapentadol starting dose was 50 mg
12-hourly; doses were then titrated, with
increments of 50 mg 12-hourly, each visit as
needed (within the therapeutic daily dose range
of 100–500 mg). Titration proceeded until
patients achieved at least a 2-point decrease in
their Numerical Rating Scale (NRS) pain score
from V0; the latter was defined as a clinically
relevant improvement in pain relief and was the
minimum target of titration. Titration
continued until at least the minimum target of
titration was reached or the patient was taking
PR tapentadol 500 mg daily. For opioid-tolerant
patients, previous opioid medication was
replaced with equianalgesic doses of PR
tapentadol. In these patients, PR tapentadol
starting doses were based on morphine
equivalent doses (MED): for an average daily
MED of B100, 101–160, or[160 mg, PR
tapentadol starting doses were 50, 100, or
150 mg 12-hourly, respectively; dose titration
and increments hence followed the scheme
illustrated for opioid-naı¨ve patients. During
the study, patients were not allowed to use
other opioids, pain killers, or adjuvant
medications.
We have hypothesized that to have lasting
analgesic efficacy, an acceptable tolerability
profile, and a positive influence on patients’
QoL and chronicity stage, the measured
outcomes should show statistically significant
stable improvement over the study time frame,
limited dropouts (\10 %), and tolerable adverse
effects.
Compliance with Ethics Guidelines
The study was approved and authorized by the
hospital’s ethics committee. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1975, as revised in 2000 and 2008, and was
conducted according to the International
Association for the Study of Pain (IASP)’s
guidelines for pain research in animals and
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Table 1 Investigated variables and tools used for data collection
Domain Tools and variable subsets
Primary pathology and concomitant pathologies Patients’ clinical history, physical exam,
clinical evidence (imaging, etc.)
Pain therapy upon recruitment Drug classes: none; paracetamol; NSAIDs;
mild or strong opioids; adjuvants
Administration schedule: ATC, PRN
Tapentadol doses at V0 and at follow-ups Mean daily dose, mg/24-h; proportions of patients with
50, 100, and 150 mg/12-hourly
Pain characteristics Pain localization: cervical spine, upper limbs, lumbar
spine, lower limbs, trunk, articulations, other (specify)
Number of pain sites: One, two, three, diffused pain
Pain duration: 0–3, 3–6, 6–12,[12 months
Pain onset cause: Spontaneous at rest; evoked by
standing up; evoked by movement, ambulation,
coughing, inspiration, sphincteral activity;
other (specify)
Pain temporal patterns: Intermittent, continuous,
episodic
Pain intensity 0–10, NRS (0 = no pain, 10 = worse pain I can
imagine)
Pain relief 0–10, NRS (0 = no relief at all, 10 = complete relief)
Patient satisfaction 1–7, NRS (1 = extremely improved, 4 = stationary,
7 = extremely worsened)
Sleep quality ‘‘In the last week your sleep was’’: 1 = profound;
2 = good; 3 = with frequent wake-ups; 4 = very
disturbed
Treatment tolerability In the advent of asthenia, vomiting, nausea, itching,
dizziness, poor appetite, dysuria, constipation,
headache; report for each: date, severity (mild,
moderate, severe), and actions taken (none, dose
reduction, therapy discontinuation, other)
General health status SF-12 which produces PCS and MCS
Chronicity stage I-MPSS which classiﬁes patients at three chronicity
stages (I mild; II moderate; and III severe CP)
Adjuvants = anti-convulsants, anti-depressants
ATC around the clock, CP chronic pain, I-MPSS 10-items Italian Mainz Pain-Staging System, MCS mental component
summary, NRS Numerical Rating Scale, NSAIDs non-steroidal anti-inﬂammatory drugs, PSC psychometrically based
physical component summary, PRN on demand, SF-12 12-items health survey
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humans. All participants were informed of the
study aims and structure and that participation
was voluntary, anonymous, and would not
affect their care. Informed consent was
obtained from all patients for inclusion in the
study.
Data Presentation and Statistical Analysis
Analyses were conducted using StatView for
Windows (SAS Institute Inc., Cary, NC, USA)
Continuous data were reported as the mean
(±standard deviation). The NRS (on a 0–10
scale) and other ordinal data were reported as
the median [95 % upper and lower confidence
intervals (CI) and interquartile range (IQR)].
Category data and proportions were expressed
in percentages. A comparison between different
follow up outcomes was made using the non-
parametric Wilcoxon signed-rank (WSR) test.
Statistical significance was defined as P\0.05.
When appropriate, P\0.01 and P\0.001 were
reported.
RESULTS
Of the 30 patients who completed the 90-day
follow-up, 66 % (n = 20) were women; the mean
age of the sample was 72.5 (±13.6) years (range
33–88). Table 2 summarizes the main clinical
features of the sample at V0. In the majority of
cases the primary pathology was lumbago with
or without sciatica (64 %); pain was localized at
one site (lower limbs 53 %), spontaneous at rest
(47 %), and had a duration of[12 months (77
%). Multiple pain medications were reported by
50 % of patients, and adjuvant ones (e.g.,
pregabalin, gabapentin, and tricyclic
antidepressants) by 33 %. The majority of
patients (76.6 %) reported further health issues
Table 2 Major characteristics of the sample at V0
Variable n (%)a
Primary pathology
Lumbago and sciatica 11 (37)
Lumbar spine 8 (27)
Cervico-brachialgia 5 (17)
Knee arthritis 4 (13)
Vertebral arthritis 3 (7)
Diabetic neuropathy 2 (7)
Arthritis and ﬁbromyalgia 1 (2)
Pain localization
Lower limbs 16 (53)
Lumbar spine 11 (37)
Upper limbs 5 (17)




Diffused pain 4 (13)
Pain onset
Spontaneous at rest 14 (47)
Evoked by standing up 7 (23)
Evoked by movement 9 (30)
Pain duration
[12 months 23 (77)
3–6 months 5 (17)










ATC around the clock, NSAIDs non-steroidal anti-inﬂammatory
drugs
a The number of cases and proportions may exceed n = 30 % and
100 % due to the multiple presence of different variable subsets in the
same patient
b Alone or in association with codeine or tramadol; regularly ATC
in n = 9, and occasionally in n = 1
c Regularly ATC
d ATC in n = 7, and occasionally in n = 6
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with a range of one to five in the same patient.
The most frequent pathology was hypertension
(43.3 %) followed by constipation,
diverticulosis, and esophagitis.
Table 3 reports the mean of tapentadol daily
dose, the number of adverse effects, the median
and interquartile range of pain intensity and
relief, patient satisfaction, and quality of sleep
from V0 to V90. Pain intensity significantly
decreased from V0 to V10 and remained stable
over time. Indeed, the WSR test showed
statistically significant differences between V0–
V10 (P = 0.0003), V0–V30, V0–V60, and V0–
V90 (P = 0.0001, respectively); significant
differences were also shown between V10–V30
(P = 0.006), but not between V30–V60 and
V60–V90 (P[0.05, respectively), indicating
stable pain reduction from the thirtieth day
onwards.
Pain relief improved from V10 to V30 and
remained stable over time. Indeed, the WSR test
showed statistically significant differences
between V10–V30 (P = 0.007), but not
between V30–V60 and V60–V90 (P[0.05,
respectively), indicating stable pain relief from
the thirtieth day onwards.
Sleep quality significantly improved from V0
to V10 and remained stable over time. Indeed,
the WSR test showed statistically significant
differences between V0–V10 (P = 0.036), V0–
V30, V0–V60, and V0–V90 (P = 0.043,
P = 0.011, P = 0.018, respectively); significant
differences were not shown between V10–V30,
V30–V60, and V60–V90 (P[0.05, respectively),
indicating stable good sleep quality from the
tenth day onwards.
For the SF-12 evaluations, psychometrically
based physical (PCS) and mental (MCS)
component summaries showed improvements
from V0 to V90 (Table 3). The WSR test showed
statistically significant differences for PCS
(P = 0.006), but not for MCS (P = 0.091).
Interestingly, while MCS showed limited
improvement, its IQR considerably decreased
from V0 to V90. When split by gender PCS and
MCS differences between V0 and V90 were
statistically significant for men (WSR, P = 0.025
and P = 0.049, respectively), but not for women.
When split by age groups PCS differences
between V0 and V90 were statistically
significant among patients of[70 years.
Proportions of chronicity stages, evaluated
with the I-MPSS questionnaire, showed an
improvement trend from V0 to V90. Indeed,
as shown in Table 3, proportions of stage I (low
chronicity) increased from 13.3 to 40.0 % and
those of stage III (high chronicity) decreased
from 40.0 to 20.0 %.
DISCUSSION
In this study we explored the lasting PR
tapentadol analgesic efficacy, tolerability
profile and influence on QoL and chronicity
stage in a cohort of non-cancer CP outpatients as
a first step towards a future trial in which the
long-term efficacy and tolerability profile of PR
tapentadol in such CP patients will be evaluated.
In agreement with other studies [6, 13–19, 22],
our data show overall satisfactory outcomes in
CP outpatients treated with PR tapentadol over a
period of 90 days. These results offer several
clinically useful observations.
Tapentadol was chosen as it was reported to
produce both satisfactory analgesia and, vs.
other strong opioids, a better tolerability
profile due to its limited opioid component
[8–12]. Indeed, evidence and its dual mode of
action (l-opioid-receptor agonist and
norepinephrine reuptake inhibitor) offer a
solid rational for it to be an efficacious, safe,
and well-tolerated analgesic in patients with
cancer and non-cancer CP [19–22].
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Initial doses of PR tapentadol were
established on the basis of pain therapy prior
to the study, while dose escalations were
dictated by the reported pain intensity at
follow-ups. Mean daily dose PR tapentadol at
V90 was roughly 50 % higher than that at V0,
indicating a satisfactory titrating process over
time. In some cases the daily dose prescribed at
V0 was relatively high (300 mg) and did not
follow the recommended titration method
Table 3 Outcome evaluations from V0 to V90
Outcome V0 V10 V30 V60 V90
Tapentadol dose
Daily dose (mg), mean (±SD) 126.7 (±58.3) 180.0 (±71.4) 186.7 (±68.1) 193.3 (±74.0) 193.3 (±74.0)
50 mg/12-hourly, n (%) 24 (80.0) 11 (36.7) 9 (30.0) 9 (30.0) 9 (30.0)
100 mg/12-hourly, n (%) 4 (13.3) 14 (46.7) 16 (53.3) 14 (46.7) 14 (46.7)
150 mg/12-hourly, n (%) 2 (6.7) 5 (16.7) 5 (16.7) 7 (23.3) 7 (23.3)
Pain intensity (NRS)a 6.0 (2.0) 4.0 (3.0) 3.0 (3.0) 3.0 (4.0) 2.0 (4.5)
Pain relief (NRS)a 5.0 (6.0) 7.0 (5.5) 7.0 (7.0) 7.5 (6.0)
Patient satisfaction (7 items)a 5.0 (2.0) 6.0 (1.5) 6.0 (2.0) 6.0 (1.5)
Sleep quality (4 items)a 3.0 (2.0) 4.0 (1.5) 4.0 (2.0) 4.0 (1.0) 4.0 (1.0)
SF-12
PCSa 29.7 (11.4) 35.8 (18.1)
MCSa 52.4 (19.1) 53.5 (3.2)
Chronicity stage [I-MPSS, n (%)]
I 4 (13.3) 12 (40.0)
II 14 (46.7) 12 (40.0)
III 12 (40.0) 6 (20.0)
Treatment side effects, n (%)
Asthenia 1 (3.3)
Chest pain 1 (3.3)
Constipation 2 (6.7) 2 (6.7) 2 (6.7)
Dyspnea 1 (3.3)




I-MPSS 10-items Italian Mainz Pain-Staging System, IQR interquartile range, MCS mental component summary, NRS
Numerical Rating Scale, PSC psychometrically based physical component summary, SD standard deviation, SF-12 12-items
health survey
a Median (IQR)
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(starting doses of 50 mg 12-hourly); this was
due to the switch done in patients already
taking high doses of strong opioids, but with
intolerable side effects.
High analgesic efficacy was shown in all
patients with rapid and significant pain
intensity reduction which was observed even
after 10 days. Pain intensity reduction further
increased and remained stable over time. These
results are in agreement with other studies in
which PR tapentadol was used to treat CP in
patients with arthritis and lumbago [14, 25, 28].
Most patients with such pathologies require
lasting pain therapy. Indeed, the majority of our
patients reported moderate/severe pain lasting
over 12 months. In our study, PR tapentadol
showed significant analgesic efficacy over a
period of 3 months, and thus may be
considered efficacious to treat lasting CP in
such patients. Reported side effects were
limited, moderate, and transitory and did not
induce patients to quit treatment.
Quality of life, functional, physical, mental,
and social issues are key concerns in the
treatment of CP. Improvement of the latter is
an essential goal of CP pharmacological
management [4, 5]. Given the long-lasting
features of CP, long-term pain treatments need
to take these issues into account and produce
analgesia, limited adverse effects, satisfactory
QoL, and physical and mental performance. In
our sample, using the SF-12 questionnaire, PCS,
and MCS summaries showed improvement over
time. Interestingly, improvements were
significant for PCS, but not for MCS; however,
MCS showed a reduction of IQR over time, thus
qualitatively and indirectly demonstrating an
improvement trend. PCS and MCS differences
between V0 and V90 were significant for men,
but not for women, and among patients
of[70 years (PCS). Widespread CP (as in
roughly 50 % of our sample) has been
reported to be associated with poor health-
related QoL and an increased risk of reporting
poor SF-12 MCS/PCS scores [29]. This was
explained by the presence of psychosocial risk
factors such as anxiety and depression for MCS
scores, and illness behavior, somatic symptoms,
depression, and sleep problems for PCS scores.
While illness behavior predicts both poor MCS
and PCS scores in CP patients, high levels of
psychological distress and anxiety are associated
specifically with poor MCS scores. For low-back
CP, illness behavior has been reported to affect
both mental and physical health-related QoL;
when pain is perceived as a threatening
symptom it tends to be catastrophized,
resulting in increased disability and depression
[30]. In our sample, even though the underlying
CP condition and possible physical and
psychosocial risk factors persisted over
3 months, an improvement trend for PCS (and
more limited for MCS) scores was shown.
Finally, the proportion of patients with
relatively high chronicity stage (II and III 87
%) was reduced over time; at V90 most patients
were classified at relatively low chronicity stage
(I and II 80 %). The I-MPSS is a ten-item
interview-administered, multi-dimensional
measure of pain chronicity. It grades CP in
terms of four pain-related axes: persistence,
spreading, medication, and healthcare
utilization; it classifies patients at three
chronicity stages (I mild; II moderate; and III
severe). These stages represent different phases
in the chronification process: the higher the
stage, the more extensive management
interventions will be needed and the less
likely a full recovery from CP will be
achieved. Chronicity staging has been also
suggested as a tool to refer patients with CP
to appropriate specialists [23, 31]. Our results
show that the PR tapentadol 12-week
treatment had a positive effect on the
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patients’ chronicity stage, and thus it might
have indirectly reduced both pain persistence,
medications, and healthcare use.
Limitations
The study’s sample size was relatively small and
no comparator was used. Because of the limited
number of available patients and similar trials
in the literature, no power analysis could have
been reported and no standards were
prospectively considered. Indeed, this study
was designed as a first step towards a future
trial in which the long-term efficacy and
tolerability profile of PR tapentadol in patients
with non-cancer CP will be compared with
other opioids. Thus, the reported study was
intended to convey an exploratory analysis in
order to gather clinical information, to validate
the set-up of the trial, and to determine an
estimate of the variability of the measurements.
Based on this study, a new randomized and
controlled study can now be more carefully
planned with a satisfactory power analysis and
an adequate sample size. The sample size also
limited the stratification of the enrolled cases in
the gender and age subgroups. To avoid analysis
type II error, due to limited cell size, along with
tentative quantitative analyses, descriptive and
qualitative analyses for these variables were also
reported, and hence they should be considered
as potential findings. Given the importance of
age and gender in CP, these findings justify
further research. Multiple comparisons and the
number of univariate analyses made in this
study may increase the risk of Type I error. To
allow interpretation, the level of P value for
each analysis was reported. As many of these
values were of high significance (P\0.01) this
risk is low. Given the consecutive nature of the
screened cases and the lack of dropouts, the
sample realistically represents our daily
practice. The external validity of this report
comes from its strong relevance in the practice
of pain medicine and the ability to highlight
important clinical outcomes in daily clinical
practice.
CONCLUSION
The results of this study add further evidence to
the satisfactory efficacy and tolerability profile
of lasting PR tapentadol in outpatients with
non-cancer CP. Along with efficacious analgesia
and limited and tolerable side effects it showed
an improvement in QoL and in functional,
physical, mental, and social issues in patients
with CP. The results are robust enough to
warrant a subsequent study with a larger
sample and longer observation time.
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